Utah Medical Products Inc (UTMD) 13F Holders & Ownership Data (117 Funds, Q2 2026)

UTMD ranks #4245 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

UTMD is a disclosed holding of Jim Simons (Renaissance Technologies), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

117 institutions disclose a position in UTMD, but none treat it as a major bet — even Minerva Advisors LLC, its most concentrated holder, allocates just 4.1% of its own portfolio to it.

Brandes Investment Partners, LP has added to its UTMD position for two straight quarters, increasing it by $13.1M to reach $32.8M today.

Barclays PLC has trimmed its UTMD position for two straight quarters, cutting it by $253.7K while still holding $60.8K.

UTMD is down 0.2% today, but institutions show net buying of $6.5M this quarter — a divergence between today's price move and the underlying institutional flow.

UTMD posted net income of $10.5M over the trailing twelve months.

• Profitable — net income of $10.5M over the trailing twelve months
• Revenue declined 7.0% year over year
• Net income declined year over year, from $12.6M to $10.5M
• Generated $14.7M in positive operating cash flow
• Current ratio of 37.62x — enough short-term assets to cover short-term liabilities
• Liabilities run 102.31x equity — a highly leveraged balance sheet worth noting